Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the use of Botulinum Toxin A as primary therapy
for children with neurogenic bladder due to spina bifida and compare results with standard
oral oxybutynin therapy. This study hopes to demonstrate that Botulinum Toxin A can maintain
or improve bladder storage function without side effects associated with oxybutynin use.
Phase:
Phase 3
Details
Lead Sponsor:
Lawson Health Research Institute
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA Mandelic Acids onabotulinumtoxinA Oxybutynin